Mississippi Medicaid (DOM)Medicaid · Coverage · Prior Authorization · MS · Endocrinology, Family Medicine, Internal Medicine +1 moreMedium impact
Insulin Update on Preferred Drug List
Act
immediately
Effective date
Jul 15, 2026
Identified
Sep 29, 2026
Summary
Mississippi Medicaid has added interchangeable biosimilar insulin glargine-yfgn (Semglee replacement) as a Preferred product on the Preferred Drug List effective immediately. Providers should prescribe this preferred insulin when clinically appropriate to ensure continued member access during the Lantus shortage and Semglee discontinuation.
Get alerts when payers change rules like this one
We check Mississippi Medicaid (DOM) and other payers every day and email you when a change matches your specialty and state.
01Billing team and providers must update prescribing and billing protocols to recognize insulin glargine-yfgn as the preferred basal insulin for Mississippi Medicaid members.
02Update EMR/EHR systems and billing software to flag insulin glargine-yfgn as preferred to reduce prior authorization denials.
03Providers should prioritize prescribing this agent when clinically appropriate for new and existing MS Medicaid patients on basal insulin therapy.
04Prior authorization requirements for preferred agents may be reduced or eliminated; verify with payer.
05Document clinical rationale if non-preferred insulin alternatives are necessary.
Codes mentioned
J7205
Original notice
Insulin Update on Preferred Drug List
medicaid.ms.gov · Always check the source before changing claims.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.